Teicoplanin—A New Use for an Old Drug in the COVID-19 Era?

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F21%3A00552498" target="_blank" >RIV/61388971:_____/21:00552498 - isvavai.cz</a>

Result on the web

<a href="https://www.mdpi.com/1424-8247/14/12/1227" target="_blank" >https://www.mdpi.com/1424-8247/14/12/1227</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/ph14121227" target="_blank" >10.3390/ph14121227</a>

Result language

angličtina

Original language name

Teicoplanin—A New Use for an Old Drug in the COVID-19 Era?

Original language description

Teicoplanin is an antibiotic that has been actively used in medical practice since 1986 to treat serious Gram-positive bacterial infections. Due to its efficiency and low cytotoxicity, teicoplanin has also been used for patients with complications, including pediatric and immunocompromised patients. Although teicoplanin is accepted as an antibacterial drug, its action against RNA viruses, including SARS-CoV2, has been proven in vitro. Here, we provide a thorough overview of teicoplanin usage in medicine, based on the current literature. We summarize infection sites treated with teicoplanin, concentrations of the antibiotic in different organs, and side effects. Finally, we summarize all available data about the antiviral activity of teicoplanin. We believe that, due to the extensive experience of teicoplanin usage in clinical settings to treat bacterial infections and its demonstrated activity against SARS-CoV2, teicoplanin could become a drug of choice in the treatment of COVID-19 patients. Teicoplanin stops the replication of the virus and at the same time avoids the development of Gram-positive bacterial co-infections.

Czech name

—

Czech description

—

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

10606 - Microbiology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Pharmaceuticals

ISSN

1424-8247

e-ISSN

1424-8247

Volume of the periodical

14

Issue of the periodical within the volume

12

Country of publishing house

CH - SWITZERLAND

Number of pages

12

Pages from-to

1227

UT code for WoS article

000773077900001

EID of the result in the Scopus database

2-s2.0-85120425693